Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
Status:
Recruiting
Trial end date:
2026-05-15
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to
investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma
gangrenosum